4,901 trials
Chronic Functional Diarrhea of Unknown Origin
Primary: Mean Change From Baseline in Blood Lead Levels During the Treatment Period and Post-treatment Follow-up Period — 0.120; 0.306; 0.095; 0.359 nanograms per millilitre…
Diabetes Mellitus, Type 1
Primary: Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentrations — 0.27; 0.17 micromole per Liter (μmol/L)
Major Depressive Disorder
Primary: Pharmacokinetics of Lorazepam, Maximum Plasma Concentration (Cmax) — 9.620; 10.720 nanograms per milliliter (ng/mL)
Healthy Volunteers
Primary: Pharmacokinetics, Area Under the Concentration-Time Curve (AUC): Medium Test Form to Reference Form — 65300; 62800 nanograms*hour per milliliter (ng*hr/mL)
Anaemia
Primary: Area Under the Concentration-time Curve (AUC) Over the Dosing Interval (AUC[0-tau]) of GSK1278863 and Its Metabolites — 184.9863; 138.6511; 162.9366; 131.2826 Hour into…
Healthy Volunteers · Diabetes Mellitus, Type 1
Primary: Part B: Glucodynamics: Endogenous Glucose Output — 64.53; 99.23; 78.05; 97.05 percent of suppression
Healthy Volunteers
Primary: Maximum Measured Concentration of Idarucizumab in Plasma (Cmax) — 30900 nanomoles (nmol) per litre (L)
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Concentration Curve From Zero to Infinity (AUC[0-∞]) of LY2409021 — 34700; 35300; 38000; 145000 nanogram*hours per milliliter (ng*h/mL)
Healthy Volunteers
Primary: Change From Baseline to Day 10 in QT Interval Corrected for Heart Rate (QTc) for LY2484595 Versus Placebo — -2.7; -4.6; -2.0; -1.1 milliseconds (msec)
Diabetes Mellitus, Type 2
Primary: Change From Baseline to Day 28 in Liver Fat Average Percent (%) — -0.47; 5.55; -1.49; 4.45 percentage of liver fat average
Dysentery, Bacillary
Primary: Concentrations of Immunoglobulin (IgG) Against Lipopolysaccharide (LPS) S. Sonnei O-antigen — 168; 5.17; 38 EU/mL
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) Following Administration of GSK2838232 Tablet…
Prostate Cancer
Primary: Change From Baseline in Tissue Gli1 Expression Levels Using qRT-PCR Analysis in Each Group (LDE225 and Observation) — 6; 0 Participants
Pharmacokinetics of Avycaz in ICU Patients
Primary: Mean (SD) Ceftazadime/Avibactam Pharmacokinetic (PK) Volume of Distribution Parameter in Intensive Care Patients — 34 Liter
Diabetes Mellitus, Type 1
Primary: Part B: Pharmacokinetics: Steady-State Concentrations in Adipose Tissue Interstitial Fluid (ISF) — 11200; 425 picomol per liter (pmol/L)